Clinical Trial Detail

NCT ID NCT03126331
Title Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

renal cell carcinoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.